A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma (KEYNOTE-224) - MK-3475-224: MK-3475 in subjects with Advanced HCC

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc0 个研究点目标入组 150 人开始时间: 2016年3月30日最近更新: 2020年12月7日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 150

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Subjects must: provide informed consent, be > or = 18 years of age, have histologically or cytologically confirmed diagnosis of HCC based on pathology report (Cohort 1), or have an HCC diagnosis confirmed by radiology, histology, or cytology (Cohort 2), have a life expectancy greater than 3 months, have Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy and not amenable to a curative treatment approach, have a Child-Pugh A liver score, have measurable disease based on RECIST 1.1 as confirmed by the blinded central imaging vendor, have ECOG Performance Scale of 0 or 1, have documented objective radiographic progression after stopping treatment with sorafenib or else intolerance to sorafenib (Cohort 1 only), be untreated for chronic HCV or 4 weeks have passed between completion of HCV therapy and start of study drug, demonstrate adequate organ function, have negative pregnancy test for females of child bearing potential prior to starting study and male and female subjects of childbearing potential must be willing to use an adequate method of contraception.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 100
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

排除标准

•The subject will be excluded from participating in the trial if the subject: is currently participating and receiving study therapy or has participated in an investigational agent and received study therapy, herbal/complementary oral or IV medicine, or used an investigational device within 4 weeks of the first dose of treatment, has received sorafenib within 14 days of first dose of study medication (Cohort 1 only), has had esophageal or gastric variceal bleeding within the last 6 months, has clinically apparent ascites on physical examination (ascites detectable on imaging studies only IS allowed), has portal vein invasion at the main portal (Vp4), inferior vena cava, or cardiac involvement of HCC based on imaging, has had encephalopathy in the last 6 months, had a solid organ or hematologic transplant, had prior systemic therapy for HCC other than sorafenib, or intercurrent local therapy to the liver tumor between sorafenib and study drug (Cohort 1), or had prior systemic therapy in the advanced disease setting (Cohort 2), has active autoimmune disease that required treatment in the past two years, has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, has received locoregional therapy to liver or major surgery to liver or other site within 6 weeks in Cohort 1 and 4 weeks in Cohort 2 prior to the first dose of study drug, has a diagnosed additional malignancy within 5 years for Cohort 1 and 3 years for Cohort 2 prior to first dose of trial treatment with some exceptions, has radiographically detectable central nervous system (CNS) metastases and/or carcinomatous meningitis, has a known history of, or evidence of, interstitial lung disease or active non-infectious pneumonitis, has an active infection requiring systemic therapy , has a known severe hypersensitivity (=Grade 3) to pembrolizumab, its active substance and/or any of its excipients, has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator, including dialysis, has known psychiatric or substance abuse disorders, is pregnant or breastfeeding, has received prior immunotherapy or previously participated in Merck pembrolizumab clinical trials, has a known history of human immunodeficiency virus (HIV), has untreated active Hepatitis B, has dual infection with HBV/HCV or other hepatitis combinations at study entry (Cohort 1 only), has dual active HBV infection (HBsAg (+) and/or detectable HBV DNA) and HCV infection (detectable HCV RNA) at study entry (Cohort 2 only), has received a live vaccine within 30 days of planned start of study therapy, with exception for killed virus vaccines used for seasonal influenza vaccines.

研究者

发起方

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc

相似试验

进行中（未招募）

1 期

A Phase 2 Study of Pembrolizumab (MK-3475) in subjects with Advanced Hepatocellular CarcinomaMedDRA version: 21.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864Hepatocellular Carcinoma

EUCTR2015-004566-28-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.150

进行中（未招募）

1 期

EUCTR2015-004566-28-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.150

进行中（未招募）

1 期

EUCTR2015-004566-28-DEMerck Sharp & Dohme LLC150

进行中（未招募）

1 期

EUCTR2015-004566-28-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.150

进行中（未招募）

1 期

A Phase II Study of Pembrolizumab (MK-3475) in subjects with previously treated Hepatocellular CarcinomaMedDRA version: 19.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864Hepatocellular Carcinoma

EUCTR2015-004566-28-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100